Skip to main content
Fig. 6 | BMC Immunology

Fig. 6

From: Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study

Fig. 6

The effect of dexamethasone and clarithromycin on the production or expression of chemokines. The protein levels of (a) CXC chemokine ligand (CXCL) 8/interleukin (IL)-8, (b) CXCL10/interferon-γ-induced protein 10 (IP-10), (c) CC chemokine ligand (CCL)11/eotaxin and (d) CCL5/regulated upon activation normal T cell expressed and secreted (RANTES) in culture supernatants, and mRNA expression levels of (e) CCL17/thymus and activation-regulated chemokine (TARC), (f) CCL20/macrophage inflammatory protein-3α (MIP-3α), (g) CCL22/macrophage-derived chemokine (MDC), (h) CXCL5/epithelial neutrophil-activating peptide-78 (ENA-78) and (i) CXCL9/monokine induced by IFN-γ (MIG) in sinonasal mucosa, from different phenotypic chronic rhinosinusitis after 24-h culture with 10−5 mol/L of dexamethasone or clarithromycin. An equivalent volume of methanol solution was used as control for dexamethasone and clarithromycin. CRSsNP, chronic rhinosinusitis without nasal polyps; Non-Eos CRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; Eos CRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; CLA, clarithromycin; CON, control; DEX, dexamethasone. n = 5 for CRSsNP group; n = 6 for Eos and Non-Eos CRSwNP group. *P < 0.05

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us